Zielinski CC - Search Results

1

Tissue expression and serum levels of HER-2/neu in patients with breast cancer.

Krainer M, Brodowicz T, Zeillinger R, Wiltschke C, Scholten C, Seifert M, Kubista E, Zielinski CC. Krainer M, et al. Among authors: zielinski cc. Oncology. 1997 Nov-Dec;54(6):475-81. doi: 10.1159/000227606. Oncology. 1997. PMID: 9394844

2

Adjuvant tamoxifen in postmenopausal patients with breast cancer and negative axillary lymph nodes.

Scholten C, Sevelda P, Kurz C, Salzer H, Kubista E, Staffen A, Czerwenka K, Spona J, Aiginger P, Zielinski CC. Scholten C, et al. Among authors: zielinski cc. Eur J Cancer. 1992;28A(12):2083. doi: 10.1016/0959-8049(92)90261-y. Eur J Cancer. 1992. PMID: 1419306 Clinical Trial. No abstract available.

3

[Effect of various factors on survival after recurrent and/or metastatic breast cancer].

Sevelda P, Kührer I, Zielinski CC, Vavra N, Seifert M, Kubista E, Czerwenka K, Spona J, Salzer H. Sevelda P, et al. Among authors: zielinski cc. Geburtshilfe Frauenheilkd. 1991 May;51(5):387-92. doi: 10.1055/s-2007-1026164. Geburtshilfe Frauenheilkd. 1991. PMID: 1869009 Clinical Trial. German.

4

Adjuvant tamoxifen in postmenopausal stage II breast cancer five years on.

Mikl J, Aiginger P, Czerwenka K, Kubista E, Salzer H, Sevelda P, Spona J, Staffen A, Zielinski CC. Mikl J, et al. Among authors: zielinski cc. Lancet. 1990 Mar 3;335(8688):541. doi: 10.1016/0140-6736(90)90775-z. Lancet. 1990. PMID: 1968551 Clinical Trial. No abstract available.

5

Plasma levels of D-dimer: a crosslinked fibrin-degradation product in female breast cancer.

Mitter CG, Zielinski CC. Mitter CG, et al. Among authors: zielinski cc. J Cancer Res Clin Oncol. 1991;117(3):259-62. doi: 10.1007/BF01625435. J Cancer Res Clin Oncol. 1991. PMID: 2033094

6

Impaired production of tumor necrosis factor in breast cancer.

Zielinski CC, Mueller C, Tyl E, Tichatschek E, Kubista E, Spona J. Zielinski CC, et al. Cancer. 1990 Nov 1;66(9):1944-8. doi: 10.1002/1097-0142(19901101)66:9<1944::aid-cncr2820660916>3.0.co;2-w. Cancer. 1990. PMID: 2224791

7

Effects of adjuvant chemotherapy on specific and non-specific immune mechanisms.

Zielinski CC, Müller C, Kubista E, Staffen A, Eibl MM. Zielinski CC, et al. Acta Med Austriaca. 1990;17(1):11-4. Acta Med Austriaca. 1990. PMID: 2353562

8

Long-term influence of adjuvant therapy on natural killer cell activity in breast cancer.

Tichatschek E, Zielinski CC, Müller C, Sevelda P, Kubista E, Czerwenka K, Spona J, Wolf H, Eibl MM. Tichatschek E, et al. Among authors: zielinski cc. Cancer Immunol Immunother. 1988;27(3):278-82. doi: 10.1007/BF00205452. Cancer Immunol Immunother. 1988. PMID: 2460239 Free PMC article.

9

Defective interferon-augmented natural killer cell activity in patients with metastatic malignant melanoma.

Müller C, Pehamberger H, Binder M, Zielinski CC. Müller C, et al. Among authors: zielinski cc. J Cancer Res Clin Oncol. 1989;115(4):393-6. doi: 10.1007/BF00400969. J Cancer Res Clin Oncol. 1989. PMID: 2474550

10

Association of increased lytic effector cell function with high estrogen receptor levels in tumor-bearing patients with breast cancer.

Zielinski CC, Tichatschek E, Müller C, Kalinowski W, Sevelda P, Czerwenka K, Kubista E, Spona J. Zielinski CC, et al. Cancer. 1989 May 15;63(10):1985-9. doi: 10.1002/1097-0142(19890515)63:10<1985::aid-cncr2820631019>3.0.co;2-b. Cancer. 1989. PMID: 2702570

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

496 results

Search Page

Filters